Aspirin Does Not Reduce Effectiveness Of ACE InhibitorsOctober 02, 2002A systematic review in this week's issue of THE LANCET provides clarification for the debate about the use of angiotensin-converting-enzyme (ACE) inhibitors in combination with aspirin for the treatment of cardiovascular disease-combination therapy does not reduce the effect of ACE inhibition. Previous research has suggested that ACE inhibitors may be less effective in patients who also receive aspirin for the treatment of cardiovascular disease. Salim Yusuf from McMaster University, Hamilton, Canada, and colleagues did a systematic overview of data from around 22,000 patients from six long-term randomised trials of ACE inhibitors to assess whether aspirin altered the effects of ACE inhibitor therapy on major clinical outcomes (a combination of death, heart attack, stroke, hospital admission for congestive heart failure, or coronary artery revascularisation). With the exception of one randomised trial, the efficacy of ACE inhibitors was not found to be altered (either positively or negatively) among patients who were also receiving aspirin. Overall, ACE inhibitor therapy significantly reduced the risk of the major clinical outcomes by 22%, with clear reductions in the risk both among those receiving or not receiving aspirin at the start of the randomised trials. Salim Yusuf comments: "Even though results from the present analyses cannot rule out the possibility of some sort of interaction, they show unequivocally that even if aspirin is given, the addition of ACE inhibitor therapy produced substantial additional benefit in all major vascular outcomes. Therefore, in the absence of clear contraindications, concomitant use of aspirin and ACE inhibitors should be considered in all patients at high risk of major vascular events." Lancet |
|||||||||||||||||||||
| Related Aspirin Current Events and Aspirin News Articles Early end to key study on benefits of niacin, a B vitamin, in keeping arteries open was premature Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Common Pain Relievers May Dilute Power of Flu Shots With flu vaccination season in full swing, research from the University of Rochester Medical Center cautions that use of many common pain killers - Advil, Tylenol, aspirin - at the time of injection may blunt the effect of the shot and have a negative effect on the immune system. News brief: Effects of aspirin and folic acid on inflammation markers for colorectal adenomas Unexpectedly, inflammation markers do not appear to be involved with the chemopreventative effect of aspirin on colorectal adenomas, according to a brief communication published online October 12 in the Journal of the National Cancer Institute. Aspirin Misuse May Have Made 1918 Flu Pandemic Worse The devastation of the 1918-1919 influenza pandemic is well known, but a new article suggests a surprising factor in the high death toll: the misuse of aspirin. Cogent trial shows lack of adverse interaction between clopidogrel and stomach medicine Results from a late breaking clinical trial called COGENT demonstrate that the combination of giving patients clopidogrel, a blood thinner commonly prescribed to patients with cardiovascular disease, and stomach medicines such as omeprazole, known as proton pump inhibitors (PPIs), did not lead to adverse events, as some prior studies had suggested. Aspirin works for primary prevention in moderate and high risk diabetics The beneficial effects of aspirin in primary prevention of cardiovascular events i.e. stroke, MI and cardiac death are known and generally accepted. New strategies for reperfusion therapy A new trial has begun in order to ascertain once and for all whether the best strategy for patients who cannot receive P-PCI is early fibrinolysis, together with mandated angiography. Small peptide found to stop lung cancer tumor growth in mice In new animal research done by investigators at Wake Forest University School of Medicine, scientists have discovered a treatment effective in mice at blocking the growth and shrinking the size of lung cancer tumors, one of the leading causes of cancer death in the world. Genetic variation associated with poorer response, cardiovascular outcomes with use of clopidogrel Patients with a certain genetic variation who received the antiplatelet drug clopidogrel had a decreased platelet response to treatment and among those who had percutaneous coronary intervention (procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries) had an increased risk of having a cardiovascular event in the following year than patients who did not have this variant, according to a study in the August 26 issue of JAMA. Study reveals mounting evidence of fish oil's heart health benefits There is mounting evidence that omega-3 fatty acids from fish or fish oil supplements not only help prevent cardiovascular diseases in healthy individuals, but also reduce the incidence of cardiac events and mortality in patients with existing heart disease. More Aspirin Current Events and Aspirin News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||